NICE in the UK issues recommendation for Sleepio app, the digital cognitive behavioural therapy for insomnia by Big Health
Sleepio becomes first digital therapeutic to receive NICE guidance (MobiHealthNews):
The National Institute for Health and Care Excellence (NICE) has recommended the Sleepio app as an effective alternative to sleeping pills.
In its guidance, NICE states the app, created by digital therapeutics (DTx) firm Big Health, is a safe and effective treatment for people suffering from insomnia.
… The Sleepio app uses an artificial intelligence (AI) algorithm to provide people with tailored digital cognitive behavioural therapy for insomnia (CBT‑I).
Jeanette Kusel, acting director for med tech and digital, NICE, said: “Our rigorous, transparent, and evidence-based analysis has found that Sleepio is cost saving for the NHS compared with usual treatments in primary care. It will also reduce people with insomnia’s reliance on dependence forming drugs such as zolpidem and zopiclone.
“This is a good example of where a digital health technology can help the NHS. The evidence has shown using Sleepio reduces the number of GP appointments people with insomnia need and will also cut the number of prescriptions for sleeping pills delivered by pharmacists.”
The new guidance by NICE (May 20th, 2022):
Sleepio to treat insomnia and insomnia symptoms
1.1 Sleepio is recommended as a cost saving option for treating insomnia and insomnia symptoms in primary care for people who would otherwise be offered sleep hygiene or sleeping pills.
1.2 For people who may be at higher risk of other sleep disorder conditions, such as in pregnancy, or in people with comorbidities, a medical assessment should be done before referral to Sleepio.
1.3 More research or data collection is recommended on Sleepio for people who are eligible for face-to-face cognitive behavioural therapy for insomnia (CBT?I) in primary care. This is because there is limited clinical evidence to show how effective Sleepio is compared with face-to-face CBT?I.
… At a price of £45 per person, Sleepio is cost saving compared with usual treatment in primary care. This is based on an analysis of primary care resource use data before and after Sleepio was introduced in 9 GP practices. Healthcare costs were lower at 1 year, mostly because of fewer GP appointments and sleeping pills prescribed.
News in Context:
- Study: Self-guided sleep app Sleepio, combined with standard care for depression and anxiety, delivers better outcomes than standard care alone
- CVS Health: Cognitive behavioral therapy (CBT) apps may help you more than sleeping pills
- First Digital Health Formulary by Express Scripts includes CBT-based programs to treat depression, anxiety and insomnia
- The FDA clears Somryst, Pear’s digital therapeutic to treat chronic insomnia
- A call to action: We need the right incentives to guide ethical innovation in neurotech and healthcare